A Multicenter Clinical Trial to Evaluate the Effectiveness of Intermittent Hypoxia Therapy in Individual With Spinal Cord Injury

Inclusion Criteria:

- History of motor incomplete spinal cord injury (AISA C and D) at or below C3, and at
or above T1 from a non-progressive etiology.

- Between the ages of 18 - 70 years.

- At least 6 months since onset of spinal cord injury.

- Ability to close and open at least one hand without assistance, without significant
use of tenodesis.

- Ability to understand and the willingness to sign an informed consent.

- Not currently (>2 weeks) taking any medications for spasticity management.

- At least a 10% change in isometric elbow strength above baseline, after a single bout
of Acute Intermittent Hypoxia (AIH), during screening (described below in detail).

Exclusion Criteria:

- Diagnosed with any of the following medical conditions: congestive heart failure,
cardiac arrhythmias, uncontrolled hypertension, uncontrolled diabetes mellitus,
chronic obstructive pulmonary disease, emphysema, severe asthma, previous myocardial
infraction, or known carotid/intracerebral artery stenosis.

- Women who are currently pregnant/nursing or planning on becoming pregnant.

- individuals with a tracheostomy or who utilize mechanical ventilation.

- Individuals who are currently enrolled in another interventional research study or in
therapy. A medical clearance will be required if patients are taking any other
investigational agents.

- Individuals who have an intrathecal baclofen pump or currently taking anti-spasticity
medications. These medications include: Baclofen (Lioresal), Clonazepam (Klonopin),
Dantrolene (Dantrium), Diazepam (Valium), or Trizanidine (Zanaflex). Subjects will be
allowed to participate in the study if they agree to wean off of these medications.

- Documented obstructive sleep apnea.

- Orthopedic injuries or surgeries that would impact an individual's ability to use the
upper extremity.

- Traumatic brain injury or other neurological conditions.